Movers and SHAKERS
Lineage Cell Therapeutics (LCTX)
Initiating Coverage, Eye of Stem Cell Treatments and Beyond
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Topline. We like how strategic and forward-looking Lineage has been recently with its pipeline programs. The management team implemented multiple changes in the corporate structure including the acquisition of Asterias Biotherapeutics - prepended two additional cell therapy product candidates, OPC1 and VAC2 in its pipeline. We believe that the value-driving components of the pipeline have been in flux and have not been on investors' radar. Our analyses show that out of the pipeline, OpRegen and VAC2 may be subject to the largest near and medium-term value inflections which could be transformational for the company and its investors.
The What. In this report, we highlight the company's innovative cell therapy pipeline as it begins to yield data. The lead program, OpRegen, is the largest contributor to our valuation with >$0.5B projected sales at peak in the age-related macular degeneration (AMD) market, which is expected to reach $18.7B sales in 2028. The second lead asset, OPC1, is in a small market of acute spinal cord ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.